A5020090012- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Function and Risk Factors
- Lipoproteins and Cardiovascular Health
- Heart Failure Treatment and Management
- Cardiovascular Disease and Adiposity
- Cardiac Arrhythmias and Treatments
- Cerebrovascular and Carotid Artery Diseases
- Cardiac electrophysiology and arrhythmias
- Hormonal Regulation and Hypertension
- Blood Pressure and Hypertension Studies
- Venous Thromboembolism Diagnosis and Management
- Peripheral Artery Disease Management
- Cardiovascular Health and Disease Prevention
- Diabetes Treatment and Management
- Atherosclerosis and Cardiovascular Diseases
- Nitric Oxide and Endothelin Effects
- Adipokines, Inflammation, and Metabolic Diseases
- Marine and coastal plant biology
- Cardiomyopathy and Myosin Studies
- Cardiac Structural Anomalies and Repair
- Cardiac pacing and defibrillation studies
Kumamoto University Hospital
1995-2025
Kumamoto University
2013-2024
Hitachi (Japan)
2024
National Cerebral and Cardiovascular Center
2014-2023
Tohoku University
1974-2023
Kishiwada City Hospital
2022
Nihon University
2002-2021
President University
2021
Tokyo Medical University
2021
Kitasato University
2000-2019
Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, inflammatory hypothesis atherothrombosis has remained unproved.We conducted a randomized, double-blind trial canakinumab, therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction high-sensitivity C-reactive protein level 2 mg or more per liter. The compared three doses canakinumab...
B-type or brain natriuretic peptide (BNP) is a novel secreted from the heart that forms family with A-type atrial (ANP), and its plasma level has been shown to be increased in patients congestive failure. This study was designed examine sources mechanisms of secretion BNP comparison those ANP control subjects failure.We measured levels as well 16 dilated cardiomyopathy (11 men 5 women; mean age, 59 years) 18 (9 9 54 by sampling blood femoral vein, aortic root, anterior interventricular vein...
Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after acute coronary syndrome.We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at dose 5 mg twice daily, with placebo, in addition standard therapy, patients recent syndrome and least two additional factors for events.The was terminated prematurely recruitment 7392 because increase major bleeding apixaban absence...
Coronary spasm plays an important role in the pathogenesis of ischemic heart diseases general. However, precise mechanism(s) responsible for coronary remains to be elucidated, and we examined molecular genetics spasm.We searched possible mutations endothelial nitric oxide synthase (eNOS) gene patients with spasm. In this study, demonstrate existence 3 linked 5'-flanking region eNOS (T-786-->C, A-922-->G, T-1468-->A). The incidence was significantly greater than control group (P<0.0001)....
<h3>Context</h3>Previous trials have investigated the effects of low-dose aspirin on primary prevention cardiovascular events, but not in patients with type 2 diabetes.<h3>Objective</h3>To examine efficacy for atherosclerotic events diabetes.<h3>Design, Setting, and Participants</h3>Multicenter, prospective, randomized, open-label, blinded, end-point trial conducted from December 2002 through April 2008 at 163 institutions throughout Japan, which enrolled 2539 diabetes without a history...
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia rehospitalization, or urgent revascularization.Follow-up the trial terminated...
BACKGROUND The plasma levels of atrial natriuretic peptide (ANP) and brain (BNP) are increased in relation to the severity congestive heart failure (CHF). This study was designed examine whether secretion patterns ANP BNP vary with underlying cardiac disorders CHF different degrees overload atria ventricles. METHODS AND RESULTS We measured aorta 20 patients mitral stenosis (MS) whom mainly overloaded, 30 dilated cardiomyopathy (DCM) both ventricles control subjects during catheterization....
BACKGROUND Brain natriuretic peptide is a novel that secreted predominantly from the ventricles, and its plasma levels have been shown to be markedly increased in patients with chronic congestive heart failure. This study was designed examine of brain as well atrial acute myocardial infarction. METHODS AND RESULTS We examined 50 consecutive (36 men 14 women; mean age, 66 years) infarction over time course 4 weeks. The level significantly on admission compared controls (92 +/- 28 versus 5.2...
The Coronary Vasomotion Disorders International Study Group (COVADIS) was established to develop international standards for the diagnostic criteria of coronary vasomotor disorders. first symposium held on 4-5 September 2013 addressed vasospastic angina, which included following (i) nitrate-responsive (ii) transient ischaemic electrocardiogram changes, and (iii) documented artery spasm. Adoption these will improve clinical diagnosis this condition facilitate research in field.
There are limited data from randomized trials evaluating the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.
Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment have been produced by the Japan Gastroenterological Endoscopy Society collaboration with Circulation Society, Japanese of Neurology, Stroke on Thrombosis and Hemostasis Diabetes Society. Previous guidelines from focused primarily prevention hemorrhage after as a result continuation ofantithrombotic therapy, without considering associated risk thrombosis. The new edition includes discussions well...
Superficial erosion of coronary plaques due to endothelial loss causes acute syndromes (ACS). Macrophages at erosive sites human atheroma present myeloperoxidase (MPO), an enzyme that produces hypochlorous acid (HOCl).Activated MPO-positive macrophages or exogenous HOCl promoted detachment cells (EC) from "Matrigel" substrata in vitro. Pathophysiologically relevant concentrations caused EC death a concentration-dependent manner: (20 50 micromol/L) induced rapid shrinkage with nuclear...
Coronary artery embolism (CE) is recognized as an important nonatherosclerotic cause of acute myocardial infarction. Its prevalence, clinical features, and prognosis remain insufficiently characterized.We screened 1776 consecutive patients who presented with de novo infarction between 2001 2013. CE was diagnosed based on criteria encompassing histological, angiographic, other diagnostic imaging findings. The characteristics, treatment strategies, in-hospital outcomes, long-term risk...
Background: Prasugrel is an antiplatelet agent that shows more prompt, potent, and consistent platelet inhibition than clopidogrel. The objective of this study was to confirm the efficacy safety prasugrel at loading/maintenance doses 20/3.75mg. Methods Results: Japanese patients (n=1,363) with acute coronary syndrome undergoing percutaneous intervention were randomized either (20/3.75mg) or clopidogrel (300/75mg), both in combination aspirin (81–330mg for first dose 81–100mg/day thereafter),...